FDA Sets the Coordinates for Safe Navigation in Genome Editing

The U.S. Food and Drug Administration has issued a draft guidance outlining standardized approaches to evaluate the safety of genome editing-based gene therapies, signaling a structured regulatory push to accelerate development while maintaining rigorous safety oversight.

The guidance, titled “Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing,” provides detailed recommendations for using next-generation sequencing (NGS) to assess off-target editing risks and genome integrity. It is intended to support nonclinical studies submitted with investigational new drug (IND) applications and Biologics License Applications (BLAs), covering both ex vivo and in vivo genome editing products.

A Framework to Standardize Safety Evaluation

Developed by the Center for Biologics Evaluation and Research (CBER), the draft builds on the agency’s January 2024 guidance and focuses specifically on NGS-based methods. It outlines expectations for sequencing strategies, sample selection, data analysis parameters, and reporting standards to comprehensively detect unintended genomic changes.

The FDA emphasizes that genome editing carries unique risks beyond traditional gene therapies, particularly off-target edits and chromosomal alterations that may affect normal cellular function. As such, the guidance recommends combining computational, biochemical, and cell-based approaches with NGS technologies to identify and confirm off-target editing sites.

Key Scientific Recommendations

The document provides a detailed roadmap for sponsors:

• Sequencing strategy: Selection of short- or long-read sequencing based on the type and size of genomic edits.
• On-target assessment: Quantification of intended edits and unintended modifications at the target site.
• Off-target analysis: Use of multiple methods, including in silico tools and NGS-based assays, to identify unintended edits.
• Chromosomal integrity: Evaluation of structural changes such as translocations, especially for editors that induce double-strand DNA breaks.
• Human genetic variation: Incorporation of population-level genomic variability to assess differential off-target risks.

Sponsors are also advised to provide detailed bioinformatics workflows, sequencing depth justification, and annotated reports of all detected editing events.

Leadership Signals a Pro-Innovation Approach

FDA Commissioner Marty Makary highlighted the agency’s intent to balance innovation with safety, noting that the guidance offers clear, science-based recommendations to evaluate off-target risks using advanced sequencing tools.

Similarly, Vinay Prasad, Chief Medical and Scientific Officer and Director of CBER, emphasized that the agency aims to provide a practical roadmap for comprehensive safety assessment while enabling efficient development of genome editing therapies.

Supporting Rare Disease Innovation

The draft guidance aligns with the FDA’s broader framework launched in February to accelerate development of individualized therapies for ultra-rare diseases. By standardizing safety evaluation methods, the agency aims to reduce uncertainty for developers and streamline regulatory pathways for transformative treatments.

Early Engagement and Next Steps

The FDA encourages sponsors to engage early through INTERACT and pre-IND meetings to discuss development strategies and safety assessment plans. The draft guidance is open for public comment for 90 days following its publication in the Federal Register, after which the agency will finalize its recommendations.

Overall, the guidance establishes a structured and science-driven foundation for evaluating genome editing therapies, reinforcing regulatory clarity as the field advances toward clinical and commercial maturity.

Reference

 FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development | FDA

Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry